A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. by Miles, D. W. et al.
British Journal of Cancer (1996) 74, 1292-1296
©) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or
without cyclophosphamide pretreatment for the active specific
immunotherapy of breast cancer
DW Miles1, KE Towlson', R Graham2, M Reddish3, BM Longenecker3, J Taylor-Papadimitriou2
and RD Rubens'
'ICRF Clinical Oncology Unit, Guy's Hospital, London SE] 9RT; 2Epithelial Cell Biology Laboratory, ICRF, 44 Lincoln's Inn
Fields, London WC2 3PX; 3Biomira Inc., Edmonton, Alberta, Canada.
Summary Studies in animal models of mouse mammary carcinoma have shown that ovine submaxillary
mucin, which carries multiple sialyl-Tn (STn) epitopes, is effective in stimulating an immune response and
inhibiting tumour growth. In similar studies using carbohydrate antigens, pretreatment with low-dose
cyclophosphamide has been shown to be important in modulating the immune response to antigen possibly by
inhibiting suppresser T-cell activity. In a clinical trial assessing the efficacy and toxicity of synthetic STn,
patients with metastatic breast cancer were randomised to receive 100 ug STn linked to keyhole limpet
haemocyanin (KLH) with DETOX-B adjuvant given by subcutaneous injection at weeks 0, 2, 5 and 9 with or
without low-dose cyclophosphamide (CTX, 300 mg m2) pretreatment, 3 days before the start of
immunotherapy. Patients with responding or stable disease after the first four injections were eligible to
receive STn-KLH at 4 week intervals. The main toxicity noted was the development of subcutaneous
granulomata at injection sites. Of 23 patients randomised, 18 received four injections, 5 patients having
developed progressive disease during the initial 12 week period. Two minor responses were noted in the 18
patients who received four active specific immunotherapy (ASI) injections and a further five patients had stable
disease. Six patients continued ASI at 4 week intervals and a partial response was noted in a patient who had
previously had stable disease. All patients developed IgG and IgM responses to sialyl-Tn and levels of IgM
antibodies were significantly higher in those patients who were pretreated with CTX. Measurable tumour
responses have been recorded following ASI with STn-KLH plus DETOX and the immunomodulatory
properties of low-dose CTX have been confirmed.
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Sialyl-Tn (STn) is defined by the structure NANAc(2-
6)GaINAc and is a carcinoma-associated core region
carbohydrate antigen of epithelial mucin. Expression of
sialyl-Tn is associated with a poor prognosis in colon
(Itzkowitz et al., 1990), gastric (Miles et al., 1995), ovarian
(Kobayashi et al., 1992) and breast cancer (Miles et al.,
1994), and may therefore be a relevant target for the
potential immunotherapy of such tumours (Longenecker et
al., 1993).
Studies in animal models have demonstrated slowing of
tumour growth and prolongation of survival following
immunisation with carbohydrate antigens (Fung et al.,
1990; Singhal et al., 1991). In a phase I study in patients
with metastatic breast cancer, immunisation with a synthetic
STn linked to keyhole limpet haemocyanin (KLH) and given
with an immunological adjuvant (DETOX-B) led to
development of hapten-specific IgM and IgG antibodies in
all patients (MacLean et al., 1993). In this study, 2 of 13
evaluable patients had a partial response to immunotherapy.
A potential method of increasing the immunogenicity of
tumour vaccines is the use of cyclophosphamide (CTX)
before immunisation. Low-dose CTX (200-300 mg m-2)
given 2-4 days before antigen administration enhances
humoral and cellular responses to vaccine immunisation in
tumour-bearing animals (Glaser, 1979; Havas and Schiff-
mann, 1981) and in man (Berd et al., 1984; Fagerberg et al.,
1995). It has been suggested that this effect is a result of
inactivation of suppressor T-lymphocytes which down-
regulate responses to novel antigens (Bonavida et al., 1979;
Berd and Mastrangelo, 1988). In malignant melanoma, CTX
pretreatment has been reported to augment cellular immunity
induced by a melanoma vaccine in patients with metastatic
disease (Berd and Mastrangelo, 1988) but not in patients with
a low tumour burden (Oratz et al., 1991).
The randomised phase II study reported here was designed
to assess whether pretreatment with low-dose CTX enhanced
the immune response to sialyl-Tn-KLH with DETOX-B in
patients with metastatic breast cancer.
Methods
Patient group
Patients with metastatic breast cancer whose disease was
assessable, who were ECOG status .2 and had an expected
survival of >6 months were eligible for this study. Patients
were required to have a lymphocyte count of x1091`
and to have been without systemic anti-tumour treatment or
radiotherapy for 6 weeks before study entry. Patients on
corticosteroids or other immunosuppressive drugs were not
eligible to enter the study.
Active specific immunotherapy (ASI) formulation preparation
Sialyl-Tn was provided as a sterile, pyrogen-free formulation
by Biomira Inc. (Edmonton, Alberta, Canada). Each vial of
STn-KLH contained 150 pg of STn-KLH in 0.75 ml of
phophate-buffered saline. DETOX-B (RIBI ImmunoChem
Research, Hamilton, MT, USA) is a sterile, pyrogen-free
preparation (Mitchell et al., 1988), and is formulated as a
lyophilised oil droplet emulsion containing monophosphoryl
lipid A and cell wall skeleton from Mycobacterium phlei.
Immediately before injection, STn-KLH was added to the
lyophilised DETOX. An aliquot of 0.5 ml of the finished
dosage form (containing 100 pg STn-KLH) was withdrawn
for injection. The administered dose consisted of 0.5 ml of
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the reconstituted emulsion of STn-KLH in DETOX-B. Half
of the volume (0.25 ml) was administered by subcutaneous
injection into two of three possible injection sites: the deltoid
region of the contralateral arm and the upper thighs
anterolaterally. Injection sites were rotated sequentially for
the subsequent treatments. Patients were randomised to
receive pretreatment with cyclophosphamide or not, 3 days
before the first ASI injection (day -3). Patients randomised
to cyclophosphamide pretreatment received a single intrave-
nous dose of 300 mg m2 with metoclopramide 20 mg i.v. On
day 0, all patients received the first vaccination of STn-KLH
in DETOX-B followed by three further injections at 2, 5 and
9 weeks. Patients who had not progressed at week 12 were
eligible to receive four further injections at monthly intervals
(weeks 13, 17, 21 and 25). Trial schema is illustrated in
Figure 1. Patients who had stable or responding disease at
week 29 could receive further injections at 3 monthly
intervals until disease progression unless the patient
requested withdrawal from the study.
Pretreatment assessment
Prestudy investigations included full
biochemical screen, chest radiograph,
with plain films of areas of increased
liver ultrasound.
blood count and
isotope bone scan
tracer uptake, and
Response assessment
Superficial lesions were measured clinically with calipers.
Other tumour dimensions were determined by appropriate
radiological investigations. Assessments were made before
treatment, at week 12 and subsequently at monthly intervals
according to a modification ofthe UICC criteria (Hayward et
al., 1977). Tumour responses were classified as follows: (1)
complete response, disappearance of all evidence of disease;
(2) partial response, >50% reduction in the sum of the
product of the two largest perpendicular diameters of all
measurable lesions with no new lesions appearing; (3) minor
response, >25% but <50% reduction in tumour lesions; (4)
stable disease, changes insufficient to enable classification into
categories 3 or 4, i.e. a decrease in the area ofall tumours less
than 25% or an increase in tumour lesions less than 25%; (5)
progressive disease, appearance of new lesions or a >25%
increase in the product of the two largest perpendicular
diameters of any individual lesion.
Time to disease progression was measured from the date
the patients started treatment to the date of detection of
progression of previously described lesions at baseline or
detection of new lesions.
Toxicity assessment
Toxicity was assessed at each clinic visit and graded
according to the National Cancer Institute common toxicity
criteria.
w
w
Prestudy screening visit
RANDOMISATION
Group A Group B
CTX 300 mg m 2 i.v., day-3
feek 1 ASI
feek 3
Week 6
Week 10
Week 13
ASI
ASI
ASI
Evaluation
Immune and/or No immune response, No immune or
clinical response stable disease clinical response,
or stable disease disease progression,
or serious adverse effects
CTX 300 mgm-2g iv.
Week 18 ASI
Week 14 ASI
Week 22 ASI
Week 26 ASI
Week 30 Evaliation
Follow-up
Figure 1 Trial schema of randomised phase II study of ASI with
and without cyclophosphamide (CTX) pretreatment. ASI con-
sisted of 100 g of STn-KLH given with DETOX-B by
subcutaneous injection.
Immune response
Titres of anti-STn IgG and IgM antibodies were measured by
quantitative enzyme-linked immunosorbent assay (ELISA) in
serum samples obtained at baseline and before each
vaccination. Microtitre 96-well plates were coated with STn-
human serum albumin (HSA) conjugate and control plates
were coated with HSA alone (values for HSA were subtracted
from STn-HSA to yield the results for STn alone), ovine
submaxillary mucin (OSM, a natural source of STn) and
KLH. Serial dilutions of serum were incubated with antigen-
coated plates at room temperature for 1 h and washed.
Alkaline phosphatase-labelled specific anti-human IgG or
IgM was added as second antibody. After washing, substrate
p-nitrophenyl phosphate substrate was added to each well.
The enzyme reaction was stopped with 1 M hydrochloric acid
and the optical densities of the resulting solutions were
measured with an automated spectrophotometer. The results
of the titration are reported as endpoint dilutions of serum
which reached 4.0 mO.D. min-'.
Results
Twenty-three patients with metastatic breast cancer were
entered into this randomised phase II study of STn-KLH in
DETOX-B adjuvant with or without cyclophosphamide
pretreatment. Patient characteristics are illustrated in Table
I. Median age of the patient group was 56 years (range 36-
73 years) and initial disease-free interval was 42 months
(range 9-89 months). Seventeen patients had received prior
endocrine therapy and 12 patients prior chemotherapy for
metastatic disease. Twenty patients had <two sites of disease
and the majority of sites were nodal and cutaneous deposits.
There were no significant differences in the above parameters
between the two patient groups (Mann-Whitney U and
Fisher's exact tests).
Eighteen patients completed at least four vaccinations
according to the protocol. Five patients were withdrawn from
the study before the first formal assessment because of
progressive disease which required alternative systemic
therapy.
Of the 18 patients assessed at week 12, 11 had progressive
disease and five had stable disease. Two patients achieved aActive specific immunotherapy of breast cancer
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minor response (<50% but >25% reduction in tumour size).
Both these patients were in the no cyclophosphamide
pretreatment group and had small bulk metastatic disease.
Patient 003, whose prior systemic treatment with tamoxifen
had been discontinued 8 months before commencing ASI,
had a minor response in a single supraclavicular fossa node
which lasted 3 months. Following the second monthly
injection, progressive disease in the lymph node was noted
and coincided with appearance of bony metastases. Patient
022, who had progressive disease following tamoxifen, had a
minor response in a single pulmonary nodule, which is
maintained 15 months following the start of ASI. Following
the four monthly injections, this patient continues to recieve
ASI at 3 monthly intervals.
Six patients received further ASI at monthly intervals and
were assessed for response at week 29. One patient, in the
cyclophosphamide pretreatment group whose disease was
stable at the week 12 assessment, achieved a partial response
of 3 months' duration in breast and cutaneous disease. One
other patient had stable disease for a period of 8 months and
the other four patients had progressive disease.
Toxicity
Toxicity associated with cyclophosphamide administration
was transient mild to moderate nausea in all patients and
transient vomiting (CTC grade II) in two patients.
Following injection of STn-KLH plus DETOX-B, all
patients developed erythema at injection sites which peaked
at 24-48 h after injection and resolved completely after a few
days. Seventeen patients developed granulomata at the
injection sites which increased in size with subsequent
injections of ASI (maximum median diameter 10 mm, range
5-60 mm, no significant differences between the two groups,
Mann-Whitney U-test). In nine patients ulceration of the
granulomata occurred and in four patients DETOX-B was
Table I Patient characteristics
Treatment group
Group A Group B
(CTXpreRx) (no CTXpreRx)
Age (years)
Median
Range
Disease-free interval (months)
Median
Range
Sites of diseases
Lymph nodes
Skin
Lung
Bone
Pleura
Breast
Liver
Ovary
Number of disease sites
1
2
3
Prior hormone therapy
(number of lines of Rx)
0
1
2
3
Prior chemotherapy
(number of lines Rx)
0
1
2
3
59
36-68
40
9-90
7
8
2
3
2
2
0
1
2
8
2
3
2
5
2
4
5
3
0
54
43-73
44
11-79
6
3
6
1
0
°1
1
5
5
1
6
2
2
7
0
2
2
omitted from subsequent injections, during the period of
monthly injections. This resulted in less granuloma formation
and no ulceration.
Systemic toxicity was limited to mild 'flu-like symptoms in
two patients in the immediate post-treated period (24-72 h)
which were treated symptomatically with paracetamol.
Antibody responses
The development of serum IgM and IgG antibodies to STn
(conjugated to human serum albumin, HSA), ovine submax-
illary mucin ( which bears multiple STn epitopes) and to
KLH were measured by quantitative ELISA before ASI, at
each treatment course and at the formal assessment of
tumour response (week 12). All patients developed IgG and
IgM responses to sialyl-Tn antigens, although levels of anti-
STn IgG antibodies were higher when measured with STn-
HSA compared with OSM. High levels of IgG antibodies to
the glycoprotein carrier KLH were noted in all patients. No
significant differences between STn or KLH antibody levels
were noted according to whether or not the patients had
received prior chemotherapy for metastatic disease. Although
levels of IgG antibodies appeared to be higher from week 5
onwards in the cyclophosphamide pretreatment group
(Figure 2), the differences were not statistically significant.
The levels of IgM antibodies to STn-HSA and OSM were
significantly higher in the group which had received
cyclophosphamide pretreatment (Figure 2).
Discussion
Specific humoral immune responses to carbohydrate antigens
have been demonstrated previously in animal models and
patients with breast, ovarian and colorectal cancer. Studies
using synthetic carbohydrate antigens in patients with breast
and ovarian cancer have previously demonstrated the
specificity of the anti-hapten humoral immune response
(MacLean et al., 1992, 1993). In the phase I study of sialyl-
Tn in patients with metastatic breast cancer, two partial
responses were noted in 13 patients and two patients had
mixed responses (reduction in tumour burden at some sites
and progression in other sites; MacLean et al., 1993).
Studies in animal models have suggested that the immune
response may be augmented by pretreatment with low-dose
cyclophosphamide, possibly by inhibition of a subset of
putative suppressor T-lymphocytes (Mastrangelo and Berd,
1988). Studies comparing the effects of i.v. CTX vs no
pretreatment on cell-mediated immunity in patients receiving
vaccine therapy for melanoma have yielded contradictory
results (Mastrangelo and Berd, 1988; Oratz et al., 1991)
possibly as a result of differences in tumour burden at the
time of treatment.
We report here the results of a randomised phase II study
assessing the effect of low-dose cyclophosphamide pretreat-
ment on the immune response to the synthetic carbohydrate
antigen, sialyl-Tn, conjugated to KLH and given with an
immunological adjuvant. The systemic toxicity of the
treatment schedule was low with only transient nausea in
those receiving CTX and mild 'flu-like symptoms associated
with ASI injections. The main toxicity of ASI was the
development of granulomas at injection sites and subsequent
ulceration. Omission of DETOX-B from the ASI formulation
alleviated this problem during subsequent treatment courses.
Measurable reductions in tumour burden were noted in two
patients following the four initial ASI injections, although
changes in dimensions of measurable lesions were not
sufficient to be categorised as a partial response according
to standard UICC criteria. Both these minor responses
occurred in patients who did not receive CTX pretreatment
and who had minimal bulk metastatic disease. A partial
response was noted in a breast mass following four further
ASI injections and, although this occurred in a patient who
received CTX pretreatment, the response was documented 29weeks following the CTX pretreatment and could not
therefore be attributed to a direct anti-tumour action of
this drug.
Following STn-KLH with DETOX, all patients developed
IgM and IgG responses to sialyl-Tn, although antibody
responses were lower when measured using OSM compared
with synthetic hapten. This has been noted previously
(Longenecker et al., 1993) and is probably caused by
differences in antibody affinity. Patients also developed
antibody responses to the glycoprotein carrier, KLH.
Although half the patients in the group had received at
least one line of chemotherapy for metastatic disease, its use
did not influence immune responsiveness in terms of antibody
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tires to STn or KLH. Low-dose cyclophosphamide
(300 mg m-2) did, however, influence the humoral immune
response. Induced levels of IgG to STn and KLH appeared
to be higher in the CTX pretreatment group, although the
apparent differences were not statistically significant. Levels
of IgM antibodies to STn were, however, significantly higher
in the CTX pretreatment group. Although levels of IgM
antibodies to KLH appeared to be higher in the CTX
pretreatment group, the differences were not statistically
significant. There was no obvious correlation between
induced levels of antibodies to STn and clinical response,
although comparison is necessarily difficult in view of the
small numbers involved.
0 2 5 9 12
Time (weeks)
Figure 2 Antibody responses (IgG and IgM) to sialyl-Tn conjugated to human serum albumin (STn-HSA), ovine submaxillary
mucin (OSM) and keyhole limpet haemocyanin (KLH) in patients receiving active specific immunotherapy (ASI) with STn-KLH
plus DETOX, with (L]) and without (*) cyclophosphamide (CTX) pretreatment (300mgm-2, day -3). ASI injection schedule is
represented by arrows. Levels of IgM antibodies to STn-HSA and OSM were significantly higher in the CTX pretreated group
(*P<0.01, **P<0.02, +P<0.05, Mann-Whitney U-test).
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In this randomised phase II study. measurable tumour
responses have been recorded using STn-KLH with DETOX
in patients with metastatic breast cancer. Treatment was well
tolerated with virtually no systemic toxicity but with
granuloma formation at the injection sites. which was
relieved by omission of the immunological adjuvant.
Although a partial response was noted in only one patient.
the possibility that this approach could influence progression-
free interval, for example following chemotherapy for
metastatic disease, should be addressed. The study has also
demonstrated that even in this heavily pre-treated group of
patients. low-dose CTX can augment the humoral immune
response to antigen and its inclusion in future studies of
specific immunotherapy in cancer should be considered.
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